Issues related to rare disease treatments, including rare disease research incentives; Issues related to the Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to drug pricing reforms.
2026 · 1st Quarter (Jan 1 - Mar 31)
ACADIA PHARMACEUTICALS, INC.
Filed by TIBER CREEK GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 18, 2026
- Income
- $80,000.00
- Expenses
- Not reported
- Registrant
- TIBER CREEK GROUP
- Filing UUID
- 48fceee7-df48-4f92-b03d-b6cfafa6412c
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.